Kornimate/medical-research-clean huggingface dataset:
evaluation of endoplasmic reticulum stress in patients with recurrent pregnancy loss

Conditions: Recurrent Pregnancy Loss; Endoplasmic Reticulum Stress

Summary: to evaluate endoplasmic reticulum stress in women with recurrent pregnancy loss and those who had healthy births in the same age group. the level of the unfolded protein x box binding protein 1 (xbp-1) is measured. it is aimed to show the effect of endoplasmic reticulum stress on recurrent pregnancy loss.


Eligibility criteria:
inclusion criteria: * with three or more miscarriages before 20 th week of gestation * had no chronic or acute inflammatory disease * used no steroids, anti-inflammatory, or antioxidant medications exclusion criteria: * had inflammatory diseases * had systemic disease * anatomical abnormalities, infectious, endocrine, or genetic etiologies
point of care 3d ultrasound for various applications: a pilot study

Conditions: Appendicitis; Evidence of Cholecystectomy; Gallstones; Pregnancy, Ectopic; Aortic Aneurysm; Kidney Stones; Intrauterine Pregnancy; Diverticulitis; Abdominal Injuries; Tumors; Pancreatitis; Digestive System Diseases; Gastrointestinal Diseases; Intraabdominal Infections; Intestinal Diseases; Pregnancy; Vascular Disease; Uterine Fibroids; Ovarian Cysts; Uterine Abnominalies; Bladder Abnominalies; Testicular Abnominalies; Polyps

Summary: summary 1. purpose and objective: the purpose of this study is to test the feasibility of rapid acquisition of point of care 3d ultrasound in obtaining abdominal and/or pelvic images. the study will use a newly developed acquisition method and post-processing technique to create three dimensional image models of the abdomen and/or pelvis. 2. study activities and population group. the study population will be a convenience sample of patients of any age presenting to the emergency department with complaints necessitating a clinical abdominal and/or pelvic imaging. the study intervention includes acquisition of research ultrasound images, which will not be used for clinical care, and comparison of these images with clinically obtained images. other clinical data such as surgical and pathology reports will also be reviewed. 3.data analysis and risk/safety issues. this is a pilot study intended to determine feasibility and to refine image reconstruction algorithms. research images will be compared to clinical images. comparison of research images with final diagnosis will also occur. the research intervention, an ultrasound exam, has no known safety risks. the only risk to subjects is loss of confidentiality. this study is observational, not interventional, because the experimental ultrasound will be performed in all subjects and will not be used in the clinical care of patients (consequently, will not have the opportunity to affect clinical outcomes). experimental images will be reviewed after completion of clinical care and will not be provided to the clinicians caring for the subjects. the investigators are not measuring the effect of the ultrasound examination on the subjects' outcomes.


Eligibility criteria:
inclusion criteria: * potential subjects must present to the emergency department for evaluation of complaints suspected to be related to an abdominal or pelvic pathology. the clinical diagnostic plan before subject enrollment may include abdominal or pelvic ultrasound, ct scan and/or mri. or * non-patient volunteer exclusion criteria: * non-english speaking

Keywords: ultrasound abdomen pelvis 3d
a study of dulanermin administered in combination with the folfox regimen and bevacizumab in patients with previously untreated, locally advanced, recurrent, or metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: this is a multicenter, open-label study enrolling a total of up to 23 patients.


Eligibility criteria:
inclusion criteria: * histologically confirmed crc with evidence of locally advanced recurrent or metastatic disease (i.e., by radiographic imaging or biopsy) and measurable tumor lesions * life expectancy \> 3 months * for patients of reproductive potential (males and females), use of reliable means for contraception throughout the trial * willingness and capability to be accessible for study follow-up exclusion criteria: * prior 5-fu, capecitabine, and/or oxaliplatin treatment with the exception of: prior oxaliplatin treatment =\ 6 months from concluding adjuvant therapy * peripheral neuropathy grade \>= 2 * prior radiotherapy to a measurable metastatic lesion(s) to be used for response assessment, unless the lesion has progressed subsequent to the radiotherapy * radiotherapy to a peripheral lesion within 14 days prior to cycle 1, day 1, or radiotherapy to a thoracic, abdominal, or pelvic field within 28 days prior to cycle 1, day 1 * chemotherapy, hormonal therapy, or immunotherapy within 4 weeks prior to cycle 1, day 1 * evidence of clinically detectable ascites * other invasive malignancies within 5 years prior to cycle 1, day 1 * current or recent participation in another experimental drug study * clinically significant cardiovascular disease, new york heart association (nyha) grade ii or greater congestive heart failure, serious cardiac arrhythmia within 1 year prior to cycle 1, day 1, or grade ii or greater peripheral vascular disease on cycle 1, day 1 * active infection requiring parenteral antibiotics * major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to cycle 1, day 1, fine needle aspirations or minor surgery (such as port placement) within 7 days prior to cycle 1, day 1, or anticipation of need for major surgical procedure during the course of the study * known or suspected to be positive for the human immunodeficiency virus (hiv) * known to be positive for hepatitis c or hepatitis b surface antigen * history of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or specified study treatment, or that might affect interpretation of the results of the study or render the patient at high risk from treatment complications * inadequately controlled hypertension * prior history of hypertensive crisis or hypertensive encephalopathy * history of arterial thromboembolic event 6 months prior to cycle 1, day 1 * history of abdominal fistula or gastrointestinal perforation within 6 months prior to cycle 1, day 1 * bleeding diathesis or coagulopathy * pregnancy (positive pregnancy test) or breast feeding * serious, non-healing wound, ulcer, or bone fracture

Keywords: crc colon cancer avastin apo2l/trail
efficiency and safety of different treatment strategies in adults with pituitary adenomas with hypothalamic involvement

Conditions: Pituitary Adenoma

Summary: prospective and randomized evaluate efficiency and safety of different treatment strategies for hypothalamus-invading pituitary adenomas (hipa)

there are various treatment strategies for hypothalamus-invading pituitary adenomas (hipa), such as total resection (tr), subtotal resection with radiosurgery (str+rs), etc. however,the optimal treatment of hipa is still controversial. in this study, we want to evaluate the efficiency and safety of different treatment strategies in adults with hipa.

Eligibility criteria:
inclusion criteria: * suspected symptomatic or progressively growing pituitary adenoma with hypothalamic involvement * informed consent exclusion criteria: * no follow-up possible * emergency surgery without informed consent

Keywords: pituitary adenoma treatment strategy hypothalamus
evaluate efficacy, tolerability & safety of combination of clindamycin and ketoconazole for the treatment of mixed-type vaginosis, bacterial vaginosis and candidiasis

Conditions: Candidiasis; Bacterial Vaginosis

Summary: the purpose of this study is to determine the efficacy, tolerability \& safety of combination of clindamycin 100mg and ketoconazole 400mg in vaginal capsules, used for 7 consecutive days in patients with mixed-type vaginosis compared to combination of tetracycline 100mg and amphotericin b 50mg in vaginal cream.


Eligibility criteria:
inclusion criteria: * mixed-type vaginosis * bacterial vaginosis * candidiasis exclusion criteria: * pregnancy * vaginal bleeding * history of recurrent vaginosis
molecular breast imaging in screening breast cancer

Conditions: Breast Cancer

Summary: the molecular breast imaging (mbi) is a potential modality to screen breast cancer. in this study, we compare and evaluate the recall rate/diagnostic efficiency of mbi, mammography and breast sonography, and aim to determine best ways of breast cancer screening.

keywords: molecular breast imaging, mbi, breast cancer, mammography, sonography 1. background: in breast cancer screening, the sensitivity of mammography is about 71-96 %, but the sensitivity decreases in the three following groups: (1) under 50 years old; (2) dense breast parenchyma; (3) higher risk of breast cancer. the health and welfare ministry data in recent 2 years showed taiwanese women accepted mammography for screening in the ratio of only about 36%, representing many missed opportunities for early detection. one reason to reject mammography may be the discomfort caused by compression. to solve the above mammography possible weakness, other screening methods came into being, such as molecular breast imaging (mbi) of nuclear medicine. radiotracer of tc-99m sestamibi was found for targeting breast tumor 20 years ago, and approved by the fda in 1997. however, the application is limited due to the suboptimal scanning camera design. ten years later, the mayo clinics developed mbi technology, using small-sized semiconductor detectors. then it become possible that the nuclear technologist have patient's breast tissue fit the detector in almost the same fashion of mammography without heavy compression. 2. objective: the aim of this study is to evaluate the recall rate and diagnostic accuracy of mbi, mammography and breast echo, for female population. 3. study design: female patients referred to nuclear medicine department for myocardial perfusion scan will be recruited in this study. it is because that mbi and myocardial perfusion scan share the same radiotracer. then mbi will become additional scanning only. about 1800 female subjects will involve, and further mammography and/or breast sonography will be arranged within 6 months after mbi. participants will be encouraged to receive mammography every 2 years and telephone survey. we hope that this study will help us to compare and evaluate the recall rate/diagnostic efficiency of mbi, mammography and breast sonography, and to determine best ways of breast cancer screening.

Eligibility criteria:
inclusion criteria: * female patients undergoing myocardial perfusion imaging will be eligible if they sign the informed consent. exclusion criteria: * they are unable to understand and sign the consent form * they are physically unable to sit upright and still for 20 minutes. * they have undergone breast surgery or breast biopsy within the last 12 months. * they have had trauma to the breast tissue or undergone radiation treatment to the breast within the last 12 months.

Keywords: molecular breast imaging mbi breast cancer mammography sonography recall rate diagnostic accuracy breast echo female population
neurocognitive and genomic predictors of persistent pain and opioid misuse after spine surgery

Conditions: Lumbar Spine Pathology; Elective Spine Surgery

Summary: having spine surgery and recovery is a vulnerable period when opioid naive patients may transition into long-term use of opioids, and when previously opioid tolerant patients may be at risk to continue towards long-term opioid use and dependence. however, little is known about risk for developing opioid misuse, taking opioids differently than indicated or prescribed, and later oud. this study addresses the question of whether behavior, cognitive features, and genomic markers can predict misuse of opioids, persistent pain and disability in individuals after spine surgery. to determine if impulsivity, inhibitory control, drug choice, and/or cognitive distortions predict opioid misuse and disability in spine surgery patients with differential gene expression. this is a prospective observational longitudinal study characterizing behavioral phenotypes in adults undergoing spine surgery using both patient-reported survey measures, cognitive testing and blood sampling. outcome measures include correlations between impulsivity measures, opioid drug choice responses and cognitive distortion scores, and opioid misuse with spine related disability, and gene expression counts.


Eligibility criteria:
inclusion criteria: * age over 18 * with diagnoses of lumbar, cervical or thoracic spine pathology, scheduled to undergo elective spine surgery with or without instrumentation exclusion criteria: * severe psychiatric condition interfering with study participation any major cardiac, pulmonary, renal, infectious, hepatic condition that interferes with study participation * polytrauma * prolonged hospitalization (\>10days) * pregnancy * known surgery cancellation within study period
outcomes of low-risk endometrial cancer with isolated tumor cells in the sentinel lymph nodes: a prospective, multicenter, cohort study

Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma; FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma; Stage IA1 Endometrial Cancer FIGO 2023; Stage IA2 Endometrial Cancer FIGO 2023

Summary: this study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.

primary objective: i. evaluate whether patients with low-risk endometrial cancer and isolated tumor cells (itc) will have worse recurrence-free survival (rfs) than a historical cohort of similar patients with negative nodes. outline: this is an observational study. patients undergo tissue sample collection and have their medical records reviewed on study.

Eligibility criteria:
inclusion criteria: * low-risk endometrial cancer, defined as endometrioid, grade 1 or 2, international federation of gynecology and obstetrics (figo) 2009 stage ia (figo 2023 stages ia1 and ia2), without substantial/extensive lvsi (≥ 5 vessels involved) at final pathology. patients with focal lvsi (\< 5 vessels involved) will be included. * complete surgical staging, including pelvic sentinel lymph node (sln) biopsy per national comprehensive cancer network (nccn) guidelines and ultrastaging. * extent of disease in sln: itc (defined as tumor cell aggregates ≤ 0.2 mm or \< 200 cells) identified in sln. * willingness to forego adjuvant treatment. * research consent provided. exclusion criteria: * prior neoadjuvant chemotherapy. * planning to receiving adjuvant treatment. * presence of synchronous cancer. * extent of disease in sln: micrometastasis (\> 0.2 to ≤ 2.0 mm) or macrometastasis (\> 2.0 mm). * presence of substantial/extensive lvsi (≥ 5 vessels involved) at final pathology. * no prior invasive cancer diagnosis within 5 years of study entry.
assessment of patients with multiple sclerosis (ms)

Conditions: Herpesviridae Infection; HTLV-I Infection; Multiple Sclerosis; Tropical Spastic Paraparesis; Vasculitis

Summary: multiple sclerosis (ms) is a disease of the nervous system. the exact cause of ms is unknown, but it is believed to be an autoimmune condition. autoimmune conditions are diseases that cause the body's immune system and natural defenses to attack healthy cells. in the case of ms, the immune system begins attacking myelin, the cells that make up the sheath covering nerves. without myelin, nerves are unable to transmit signals effectively and symptoms occur. this study is directed toward a better understanding of the cause of multiple sclerosis (ms). researchers will evaluate patients with a tentative diagnosis of ms or other neurological diseases possibly caused by a immunological reaction. patients will undergo a series of three mris, taken once a month for three months and submit blood samples for immunological studies.

the neuroimmunology branch (nib) conducts research into the cause of immunologically mediated diseases of the nervous system such as multiple sclerosis (ms). the studies in the nib range for studies of the natural history of ms to trials of new experimental therapies. in order to recruit patients into the various nib research studies, patients with a tentative diagnosis are initially seen by the nib to assess the accuracy of the diagnosis and to assess the level of disease activity occurring in the patient. patients seen under the nib screening protocol are evaluated in clinic with a complete neurological examination. blood studies necessary to eliminate the possibility of many other causes of disease that may resemble ms are performed. spinal fluid examination may be preformed if uncertainty exists with respect to the diagnosis. finally, patients will have at least one mri preformed to assess the consistency with mri findings expected in ms. most patients will have a series of three mris done approximately one month apart in order to assess the frequency of new contrast enhancing lesions occurring in the patient. the level of disease on mri is important both from the standpoint of diagnosis as well as determining if the patient may be eligible for any other nib protocols. to assess the patient's eligibility for other nib studies, the nib may periodically follow patients in whom the diagnosis is uncertain or in whom the level of disease activity is not clear for the initial evaluation.

Eligibility criteria:
* inclusion criteria: diagnosis of possible ms. age between 18 and 75. exclusion criteria: clinically significant medical condition other than ms that could cause neurological dysfunction. currently enrolled in an experimental study. medical contraindication for mri. psychological contraindications for mri. unable to provide informed consent.

Keywords: immunogenetics tropical spastic paraplegia twins epstein-barr virus htlv-i vasculitis cerebrospinal fluid immunity to viruses multiple sclerosis magnetic resonance imaging
failed endometrial ablation treatment with implantable progesterone (feat) study

Conditions: Abnormal Uterine Bleeding; Dysmenorrhea

Summary: the objective of this study is to assess the efficacy of an implantable etonogestrel device in reducing hysterectomy rate in patients with a failed endometrial ablation.

the researchers aim to determine whether use of etonogestrel implant in patients with failed endometrial ablation significantly decreases hysterectomy rate. changes in pelvic pain and vaginal bleeding will be assessed. time to hysterectomy will be examined. the researchers hypothesize that treatment of failed endometrial ablation with etonogestrel implant will decrease pelvic pain and vaginal bleeding resulting in a significantly decreased need for hysterectomy.

Eligibility criteria:
inclusion criteria: * previous endometrial ablation * pelvic pain and/or vaginal bleeding seeking treatment exclusion criteria: * previous or current vte * liver tumour, benign or malignant, or active liver disease * undiagnosed abnormal genital bleeding * known or suspected breast cancer * uncontrolled hypertension * allergy to component of etonogestrel implant * lack of patient consent

Keywords: abnormal uterine bleeding pain dysmenorrhea endometrial ablation
a preliminary feasibility efficacy of participation in daily life promotion program

Conditions: Stroke

Summary: efficacy of participation in daily life promotion program for patients with chronic stroke

the purpose of this three-year research project is to develop an intervention program to promote participation in daily life for patients with chronic stroke and to evaluate its efficacy.

Eligibility criteria:
inclusion criteria: * patient with stroke after 6 months. * must be able to follow orders and no other cognition impairment, mini mental state examination scale must \>20. exclusion criteria: * clinical diagnosis of dementia or psychosis. * clinical diagnosis of musculoskeletal disorders or nervous system diseases. * patient with congestive heart failure, hypertension, atrial fibrillation. * could not communication with others. * foreigner.

Keywords: life participation
conditioning treatment with umbilical cord blood transplant for hematologic malignancies

Conditions: Hematologic Malignancies

Summary: this is a phase ii study to assess the day 180 event free and overall survival after administration of a specified combination of fludarabine, busulfan, total body irradiation (tbi), and thymoglobulin reduced intensity conditioning and 2 unit ucb stem cell transplant in a single institution setting in patients with hematologic malignancies for whom allogeneic transplantation is indicated.


Eligibility criteria:
inclusion criteria: subjects 18-70 years old. ecog 0-2 patients must have a diagnosis of one of the following: * chronic myeloid leukemia * acute myeloid leukemia * acute lymphoblastic leukemia * hodgkin's disease * non-hodgkins lymphoma * myelodysplastic syndromes * myeloproliferative disorder patients must have adequate visceral organ function * patients must furnish written informed consent and hipaa authorization for release of personal health information. * patients must be able to understand the requirements of the study, abide by the study restrictions, and agree to return for the required assessments. exclusion criteria: * patients who have a histocompatible sibling-matched donor age 18 to 65 years in good health who is willing to donate stem cells are ineligible. * patients who are pregnant are ineligible. * patients are ineligible if they have received cumulative chemotherapy doses in excess of: carmustine (bcnu) 400 mg/m2, and/or a cumulative anthracycline exposure in excess of 550 mg/m2 doxorubicin (adriamycin®) unless gated-pool radionuclide cardiac scan shows greater than/equal to 45% ejection fraction. patients who are hiv or htlv-i, -ii antibody sero-positive are ineligible.

Keywords: chronic myeloid leukemia acute myeloid leukemia acute lymphoblastic leukemia non-hodgkins lymphoma hodgkin's disease myelodysplastic syndromes myeloproliferative disorder